EUVIMEDEUVIMED entdecken
Crossref

Dexmedetomidine and postoperative dementia risk in older patients

Mingyang Sun, Shaihao Fu, Tian Mao, Wei Li, Shaoxuan Cai, Xiaojuan Xie, Wan-Ming Chen iD, Szu-Yuan Wu iD, Jiaqiang Zhang

Age and Ageing · 29.08.2025 · 54 (9)

DOI: 10.1093/ageing/afaf258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 17.09.2025. Verfasst von Mingyang Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, He…. Hauptthemen laut MEDLINE: Dexmedetomidine, Dementia, Adrenergic alpha-2 Receptor Agonists, Hip Fractures. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Postoperative cognitive decline (POCD) and dementia are significant risks in older patients after surgery. Dexmedetomidine, an α2-adrenergic agonist, has shown neuroprotective properties in preclinical models, but its role in preventing dementia in postoperative patients remains unexplored.

Methods

We conducted a retrospective cohort study using data from Taiwan’s National Health Insurance Research Database from 2012 to 2020. The cohort included 59 194 older patients (≥70 years) who underwent hip fracture surgery. Patients were categorised based on postoperative dexmedetomidine use. The primary outcome was the incidence of dementia, including Alzheimer’s disease (ad) and vascular dementia (VaD), assessed using multivariable Cox regression models adjusted for confounders. Competing risk analysis was also performed.

Results

Patients administered dexmedetomidine postoperatively had a significantly lower risk of dementia compared to those who did not receive the drug [adjusted hazard ratio (aHR) 0.53, 95% confidence interval (CI) 0.45–0.60]. The reduction in ad risk was more pronounced (aHR 0.38, 95% CI 0.30–0.47) compared to VaD (aHR 0.58, 95% CI 0.49–0.68). These effects persisted after adjusting for confounders, including age, sex, comorbidities, and socioeconomic factors.

Conclusions

This study is the first to provide clinical evidence supporting dexmedetomidine’s potential in reducing dementia risk, particularly ad, in older postoperative patients. Further randomised trials are needed to confirm these findings and determine the optimal use of dexmedetomidine in postoperative care. If validated, dexmedetomidine could become a critical strategy in reducing the long-term cognitive burden in ageing populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineDementiaAdrenergic alpha-2 Receptor AgonistsHip FracturesPostoperative Cognitive ComplicationsPostoperative ComplicationsHumansAgedMaleFemaleRetrospective StudiesAged, 80 and overTaiwanRisk FactorsIncidenceRisk AssessmentDatabases, FactualAge Factors

Stichwörter der Autor:innen

Alzheimer’s diseasedementia preventiondexmedetomidineolder patientsolder peoplevascular dementia

Substanzen

DexmedetomidineAdrenergic alpha-2 Receptor Agonists

Autor:innen und Institutionen

  • Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
  • Academy of Medical Sciences of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Anesthesiology and Perioperative Medicine, People's Hospital of Henan University, Zhengzhou, Henan, China.
  • Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China.
  • Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan.
  • Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan.

ORCID-Profile: Wan-Ming Chen, Szu-Yuan Wu

Förderung

  • Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Sun, M., Fu, S., Mao, T., Li, W., Cai, S., Xie, X., Chen, W. M., Wu, S. Y., & Zhang, J. (2025). Dexmedetomidine and postoperative dementia risk in older patients. Age and Ageing, 54(9). https://doi.org/10.1093/ageing/afaf258

Vancouver

Sun M, Fu S, Mao T, Li W, Cai S, Xie X, et al. Dexmedetomidine and postoperative dementia risk in older patients. Age and Ageing. 2025;54(9). doi:10.1093/ageing/afaf258

BibTeX
@article{Sun2025,
  author = {Sun, Mingyang and Fu, Shaihao and Mao, Tian and Li, Wei and Cai, Shaoxuan and Xie, Xiaojuan and Chen, Wan-Ming and Wu, Szu-Yuan and Zhang, Jiaqiang},
  title = {Dexmedetomidine and postoperative dementia risk in older patients},
  journal = {Age and Ageing},
  year = {2025},
  volume = {54},
  number = {9},
  doi = {10.1093/ageing/afaf258}
}
Kostenlos starten →